Prevalence of Urgency in Patients with LUTS Due to BPE
Purpose of Review
To review recent data on the prevalence and treatment of the symptom of urgency in men with benign prostatic enlargement (BPE).
In recent years, researchers have moved to separate out individual lower urinary tract symptoms (LUTS) to see the individual impact. A recent registry trial put the prevalence of urgency at 38% in men with BPE. Other studies have reported urgency present in 64% of men with LUTS. While urgency is not as frequent a complaint in BPE as nocturia and frequency, it does have an impact on health-related quality of life. It is not increased in men with diabetes or the metabolic syndrome. Contributing factors may include prostate inflammation and decreased bladder blood flow from outlet obstruction. While some response is seen with treatment with alpha-blockers, more recently, anticholinergic and beta 3 medications are being used for refractory urgency in men with BPE.
Urinary urgency is commonly reported in men with benign prostatic enlargement and is just beginning to be better evaluated with screening tools commonly used in overactive bladder patients. Specific medical therapy for urgency is helping to improve the response rate above traditional BPE therapy.
KeywordsUrgency BPH BPE LUTS Prevalence
Compliance with Ethical Standards
Conflict of Interest
Dr. Sih and Dr. Angel have no conflicts of interest. Dr. Pontari was paid consultant fees from Aquinox and Allergen.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently have been highlighted as: •Of importance
- 3.Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. https://doi.org/10.1002/nau.10052.CrossRefPubMedGoogle Scholar
- 4.Tam CA, Helfand BT, Erickson BA. The relationship between diabetes, diabetes severity, diabetes biomarkers, and the presence of lower urinary tract symptoms: findings from the national health and nutrition examination survey. Urology. 2017;105:141–8. https://doi.org/10.1016/j.urology.2017.03.040.CrossRefPubMedGoogle Scholar
- 7.Jeong SM, Suh B, Jang SH, Jin HS, Kim N, Kwon H, et al. Depression and its severity are strongly associated with both storage and voiding lower urinary tract symptoms independently of prostate volume. J Korean Med Sci. 2015;30(11):1646–51. https://doi.org/10.3346/jkms.2015.30.11.1646.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Russo GI, Cimino S, Fragalà E, Privitera S, La Vignera S, Condorelli R, et al. Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. World J Urol. 2015;33(5):743–51. https://doi.org/10.1007/s00345-014-1392-4.CrossRefPubMedGoogle Scholar
- 9.Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14. https://doi.org/10.1016/j.eururo.2006.09.019.CrossRefPubMedGoogle Scholar
- 11.Miranda Ede P, Gomes CM, Torricelli FC, Júnior d BJ, de Castro JE, Ferreira BR, et al. Nocturia is the lower urinary tract symptom with greatest impact on quality of life of men from a community setting. Int Neurourol J. 2014;18(2):86–90. https://doi.org/10.5213/inj.2014.18.2.86.CrossRefPubMedGoogle Scholar
- 12.• Rohrmann S, Katzke V, Kaaks R. Prevalence and progression of lower urinary tract symptoms in an aging population. Urology. 2016;95(158):158–63. https://doi.org/10.1016/j.urology.2016.06.021. This study followed lower urinary tract symptoms and demonstrated both improvement and worsening of symptoms over a 3-year period, reinforcing that LUTS are not static and are prone to change.CrossRefPubMedGoogle Scholar
- 14.Tubaro A, Berges R, Caris C, De la Taille A, Esperto F, Martinez-Pinero L, et al. The prevalence of urgency in patients with lower urinary tract symptoms due to benign prostatic enlargement. Analysis of the Evolution Registry. J. Urol. 2016;195(suppl 4S):e480. Abstract MP35-06. https://doi.org/10.1016/j.juro.2016.02.1598.Google Scholar
- 17.Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(6):1379–84. https://doi.org/10.1016/j.eururo.2007.11.026.CrossRefPubMedGoogle Scholar
- 20.Cartwright R, Mangera A, Tikkinen KA, Rajan P, Pesonen J, Kirby AC, et al. Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur Urol. 2014;66(4):752–68. https://doi.org/10.1016/j.eururo.2014.01.007.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Tacklind J, Fink HA, MacDonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010;(10):CD006015. https://doi.org/10.1002/14651858.CD006015.pub3.
- 22.Kaplan S, He W, Koltun W, Cummings J, Schneider T, Fakhoury A. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol. 2013;63(1):158–65. https://doi.org/10.1016/j.eururo.2012.07.003.CrossRefPubMedGoogle Scholar
- 23.• Drake MJ, Sokol R, Coyne K, Hakimi Z, Nazir J, Dorey J, et al. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. BJU Int. 2016;117(1):165–72. https://doi.org/10.1111/bju.13162. The addition of the anticholinergic medication solifenacin to the alpha-blocker tamsulosin resulted in a significant improvement in LUTS compared to tamsulosin alone. The reduction in the urgency as measured by the Total Urgency Frequency Score (TUFS) and health-related quality of life.CrossRefPubMedGoogle Scholar
- 26.• Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921–6. https://doi.org/10.1016/j.juro.2014.09.091. The addition of mirabegron 50 mg to daily tamsulosin significantly improved symptoms of overactive bladder compared to tamsulosin alone in men with BPE and urgency at least once per week.CrossRefPubMedGoogle Scholar
- 27.Wagg A, Cardozo L, Nitti V, Castro-Diaz D, Auerbach S, Blauwet M, et al. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666–75. https://doi.org/10.1093/ageing/afu017.CrossRefPubMedGoogle Scholar